menu
    • menu
    [{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Alzheimers Drug Discovery Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Astrocyte Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Alzheimers Drug Discovery Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Astrocyte Pharmaceuticals \/ Alzheimers Drug Discovery Foundation"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Astrocyte Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AST-004","moa":"Adenosine A1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astrocyte Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astrocyte Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astrocyte Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"AST-004","moa":"Adenosine A1 receptor (ADORA1)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Astrocyte Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astrocyte Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Astrocyte Pharmaceuticals \/ National Institutes of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Astrocyte Pharmaceuticals

    Menu

    Astrocyte Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AST-004

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Astrocyte Announces New $3M NIH Grant for the Development of AST-004

                            Details : The funding will be used to accelerate the development of an easy-to-use oral version of AST-004 in order to make the drug more readily available to patients and athletes.

                            Product Name : AST-004

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 17, 2025

                            Lead Product(s) : AST-004

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AST-004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astrocyte Gets FDA Clearance for AST-004 IND Application

                            Details : Astrocyte AST-004, an innovative small molecule therapy, which is an adenosine A3/A1 receptor agonist, is being evaluated in Phase I clinical trial studies with patients for Acute Ischemic Stroke.

                            Product Name : AST-004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : AST-004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AST-004

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Alzheimers Drug Discovery Foundation

                            Deal Size : $6.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Alzheimer's Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to E...

                            Details : The funding will accelerate the development of AST-004, a small molecule adenosine A3/A1 receptor agonist, aimed at treating acute brain injuries including stroke and traumatic brain injury (TBI), and further assess its potential in preclinical models of...

                            Product Name : AST-004

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 18, 2023

                            Lead Product(s) : AST-004

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Alzheimers Drug Discovery Foundation

                            Deal Size : $6.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AST-004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brai...

                            Details : AST-004 is a small molecule adenosine A3/A1 receptor agonist, it is being investigated as an extended infusion for stroke and traumatic brain injuries.

                            Product Name : AST-004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 04, 2023

                            Lead Product(s) : AST-004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AST-004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research ...

                            Details : AST-004 was extremely well tolerated at all dose levels, and there have been no safety signals or significant adverse effects associated with AST-004.

                            Product Name : AST-004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 14, 2022

                            Lead Product(s) : AST-004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Astrocyte Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AST-004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Inj...

                            Details : AST-004 has demonstrated a broad range of cerebroprotective efficacy when treating preclinical animal models, including preserving up to 45 percent more brain tissue in a non-human primate model of stroke, beyond that of reperfusion standard of care.

                            Product Name : AST-004

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 15, 2022

                            Lead Product(s) : AST-004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth